Mackenzie Financial Corp Has $57.52 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Mackenzie Financial Corp raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 199,710 shares of the medical research company’s stock after purchasing an additional 1,429 shares during the period. Mackenzie Financial Corp’s holdings in Amgen were worth $57,520,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in AMGN. Hoxton Planning & Management LLC acquired a new stake in Amgen during the 4th quarter worth approximately $201,000. Dakota Wealth Management boosted its holdings in Amgen by 8.3% during the fourth quarter. Dakota Wealth Management now owns 29,140 shares of the medical research company’s stock worth $8,393,000 after purchasing an additional 2,245 shares during the last quarter. Cullen Investment Group LTD. bought a new position in Amgen in the fourth quarter valued at $2,503,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen in the 4th quarter valued at $29,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its position in Amgen by 1.2% during the 4th quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 11,515 shares of the medical research company’s stock worth $3,317,000 after buying an additional 141 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the subject of several analyst reports. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. SVB Leerink downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. UBS Group decreased their target price on Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a report on Monday, January 29th. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and raised their price target for the company from $264.00 to $320.00 in a report on Thursday, December 21st. Finally, BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $286.00 to $326.00 in a research report on Tuesday, December 19th. Ten analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $295.30.

Amgen Stock Performance

Shares of Amgen stock opened at $265.64 on Wednesday. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market capitalization of $142.36 billion, a P/E ratio of 21.27, a P/E/G ratio of 2.53 and a beta of 0.58. The company’s 50 day moving average price is $278.62 and its two-hundred day moving average price is $281.49.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same quarter last year, the business posted $4.09 earnings per share. The company’s quarterly revenue was up 19.8% on a year-over-year basis. On average, equities analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.39%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.